#United States #California #Securities Fraud #deramiocel #Capricor Therapeutics

Capricor Therapeutics Class Action Lawsuit

Capricor Therapeutics, Inc. has recently come under fire as a class action lawsuit has been initiated against it following a staggering 64% decline in its stock price. The lawsuit, announced by the prominent securities law firm Bleichmar Fonti & Auld LLP, centers on allegations of securities fraud, claiming that the company misrepresented information related to its product Deramiocel and the accompanying clinical data pivotal for its Biologics License Application (BLA).

Background of the Company and Its Products

Capricor Therapeutics is a biotechnology firm primarily focused on innovating cell and exosome-based therapies for rare diseases. Their flagship candidate, Deramiocel, is a therapeutic cell treatment designed for Duchenne muscular dystrophy, a debilitating genetic disorder that results in muscle degeneration.

In late 2024, Capricor submitted a BLA for Deramiocel to the FDA. However, trouble started brewing when, in July 2025, the FDA issued a Complete Response Letter, indicating that the application lacked sufficient evidence of efficacy and required further clinical data. It was later alleged that Capricor did not disclose critical changes made to the statistics analysis plan before resubmitting the BLA, leading to serious questions about the integrity of their clinical data.

A Sudden Decline in Stock Value

The situation escalated on July 27, 2026, when the FDA shared briefing documents that raised critical concerns about amendments made to Capricor’s statistical methods just days before the critical database was unlocked. Following this revelation, shares plunged from a closing price of $19.70 to $7.00, marking a notable loss of $12.70 per share and a staggering 64.5% drop in value.

Further compounding the situation, an FDA advisory committee meeting held shortly afterward prompted additional scrutiny. This culminated in a non-binding vote indicating that evidence did not support Deramiocel’s effectiveness against DMD-associated cardiomyopathy. Consequently, Capricor's stock underwent another sharp decline, dropping by 36% over the course of two days.

Lawsuit Details

The class action has been filed in the U.S. District Court for the Southern District of California, specifically in the case titled Nkamga v. Capricor Therapeutics, Inc. et al. Investors who feel they may have been adversely affected by these events have a deadline to file their claims by September 28, 2026. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, which protects investors from undue losses stemming from securities fraud.

Guidance for Investors

Investors who have purchased Capricor securities are encouraged to act promptly to understand their legal rights. Individuals impacted by this drop in stock value may find representation through Bleichmar Fonti & Auld LLP under a contingency fee arrangement, meaning no upfront costs are required, and they are not liable for litigation expenses unless successful.

For those seeking more information on how the lawsuit may affect their investments or on how to join the class, the law firm provides an avenue for inquiries through their dedicated website.

Conclusion

As the legal battle unfolds, Capricor Therapeutics and its investors will have to navigate the turbulent waters of this class action lawsuit. With implications for the company's future, particularly surrounding the development and approval of Deramiocel, this case serves as a crucial reminder of the importance of transparency and integrity in the biotech sector. Investors are urged to stay informed and approach the situation with caution as further developments arise.